Johnson & Johnson has moved a step closer to filing a potential first-in-class therapy for psoriasis after the drug hit the mark in a phase 3 trial. Once-daily oral IL-23 inhibitor icotrokinra (fo ...

GenBank accession numbers are given beside the strain numbers and bootstrap probability values (based on 1000 replications ... pure strains for thiocyanate degradation were also examined. Plots of ...